 global molecular hemostat marker acut myeloid leukemia patient acut myeloid leukemia hemostat thrombot complic intravascular coagul previou studi routin coagul analys use inform patient studi first comprehens evalu variou aspect hemostat system popul patient acut myeloid leukemia eighteen patient year age diagnosi relaps hemostat studi onset day initi therapi bone marrow blast count prothrombin time partial thromboplastin time minor prolong patient patient measur platelet-associ marker elev platelet factor thromboxan normal alpha level fibrinolyt marker increas d-dimer tissu plasminogen activ decreas alpha level plasminogen plasminogen activ inhibitor fibrinogen level normal coagul marker decreas protein antithrombin iii level elev thrombin-antithrombin complex pretreat valu hemostat marker similar valu day treatment investig subclin activ compon hemostat system hypercoagul state patient hemorrhag complic risk and/or thrombosi evid patient signific abnorm level specif molecular marker hemostasi futur applic marker clinic evalu leukem patient risk coagul disord